Document is current
Any future updates will be listed below
-
Authors
Suzuki, Shigeki
Asakura, Keisuke
Okui, Masayuki
Izawa, Naoko
Sawafuji, Makoto
Sakamaki, Hiroyuki
Shigenobu, Takao
Tajima, Atsushi
Oka, Naoyuki
Masai, Kyohei
Kaseda, Kaoru
Hishida, Tomoyuki
Yasuda, Hiroyuki
Fukunaga, Koichi
Asamura, Hisao
-
Funding
Funding for this research was provided by:
Covidien Japan Inc.
Daiichi Sankyo Co., Ltd.
Eli Lilly Japan K.K.
Shionogi & Co., Ltd.
Chugai Pharmaceutical Co., Ltd.
Kyowa Kirin Co., Ltd.
Taiho Pharmaceutical Co., Ltd
- License Information
-
More Information
Article History
Received: 21 June 2023
Accepted: 9 September 2023
First Online: 15 September 2023
Declarations
:
: The study was approved by the Ethics Committee of Keio University School of Medicine (approval no. 20200092) and the ethical committees of the other three participating Keio University-affiliated hospitals.
: The need for informed consent for publication was waived according to the policy of our IRB.
: The authors KA, NO, KM, KK, TH, and HA have declared competing interests, having received unrestricted institutional funds from several companies including the following: Chugai Pharmaceutical Co., Ltd.; Covidien Japan Inc.; Daiichi Sankyo Co., Ltd.; Eli Lilly Japan K.K.; Kyowa Kirin Co., Ltd.; Shionogi & Co., Ltd.; and Taiho Pharmaceutical Co., Ltd. The other authors declare that they have no competing interests.
